Tenpoint names Carol Kearney CCO

Privately-held Tenpoint Therapeutics, a UK-headquartered biotech focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, has announced the appointment of Carol Kearney (pictured, above) as chief commercial officer (CCO).

In this role, Ms Kearney will be spearheading Tenpoint’s commercial strategy, including preparation of the potential US launch of Brimochol PF, an investigational, preservative-free, once-daily eye drop designed to address the loss of near vision.

Ms Kearney is an established commercialization executive with more than two decades of leadership experience in the biopharmaceutical industry, working with both private- and publicly-traded biotech companies.